Natural endogenous material-based vehicles for delivery of macromolecular drugs

Abstract

Natural endogenous materials (NEMs), such as cell and cell derivatives, polysaccharide, protein and peptide, and nucleic acid-derived vectors, often exhibit biocompatibility, biodegradability and natural homing ability, which can minimize adverse reactions in vivo and have the potential to improve drug delivery efficacy. Currently, a variety of drug delivery systems (DDSs) based on NEMs have been constructed for macromolecules to address the challenges posed by their inherent large size, intricate structure, low permeability, and susceptibility to harsh environments. The aim of this article is to provide a comprehensive overview of various delivery strategies that predominantly utilize NEMs as carriers for macromolecular delivery. By thoroughly discussing the pros and cons of NEM-based DDSs, we hope to provide valuable insights into future innovations in pharmaceutical science, with a focus on improving therapeutic outcomes through advanced drug formulations.

Keywords

Macromolecular delivery / Endogenous material / Cell and cell derivatives / Exosome / Protein and peptide-based carrier / Nucleic acid-derived vector

References

[1] Luo Z, Cerrejon DK, Römer S, et al. Boosting systemic absorption of peptides with a bioinspired buccal-stretching patch[J]. Sci Transl Med, 2023, 15(715): eabq1887.

[2] Jiang L, Sun Y, Lu A, et al. Ionic liquids: promising approach for oral drug delivery[J]. Pharm Res, 2022, 39: 2353-2365.

[3] Yang Y, Zhou R, Wang Y, et al. Recent advances in oral and transdermal protein delivery systems[J]. Angew Chem Int Ed Engl, 2023, 62(10): e202214795.

[4] Banerjee A, Ibsen K, Brown T, et al. Ionic liquids for oral insulin delivery[J]. Proc Natl Acad Sci U S A, 2018, 115(28): 7296-7301.

[5] Zhai L, Shi YJ, Yan Y, et al. Local sustained release of PD-1 monoclonal antibody and lenvatinib by thermo-sensitive hydrogel for improving tumor immunotherapy[J]. Chin Chem Lett, 2023, 34(8): 108104.

[6] Shi Y, Lu A, Wang X, et al. A review of existing strategies for designing long-acting parenteral formulations: focus on underlying mechanisms, and future perspectives[J]. Acta Pharm Sin B, 2021, 11(8): 2396-2415.

[7] Yan J, Bhadane R, Ran M, et al. Development of aptamer-DNAzyme based metal-nucleic acid frameworks for gastric cancer therapy[J]. Nat Commun, 2024, 15(1): 3684.

[8] Mohamed M, Abu Lila AS, Shimizu T, et al. PEGylated liposomes: immunological responses[J]. Sci Technol Adv Mater, 2019, 20(1): 710-724.

[9] Estapé Senti M, de Jongh CA, Dijkxhoorn K, et al. Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement[J]. J Control Release, 2022, 341: 475-486.

[10] Wang L, Zhang Y, Ma Y, et al. Cellular drug delivery system for disease treatment[J]. Int J Pharm, 2023, 641: 123069.

[11] Liu H, Su Y, Jiang X, et al. Cell membrane-coated nanoparticles: a novel multifunctional biomimetic drug delivery system[J]. Drug Deliv Transl Res, 2023, 13(3): 716-737.

[12] Liang Y, Duan L, Lu J, et al. Engineering exosomes for targeted drug delivery[J]. Theranostics, 2021, 11(7): 3183-3195.

[13] Chen G, Kang W, Li W, et al. Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies[J]. Theranostics, 2022, 12(3): 1419-1439.

[14] Lee SY, Kang MS, Jeong WY, et al. Hyaluronic acid-based theranostic nanomedicines for targeted cancer therapy[J]. Cancers (Basel), 2020, 12(4): 940.

[15] Han J, Wang Q, Zhang Z, et al. Cationic bovine serum albumin based self-assembled nanoparticles as siRNA delivery vector for treating lung metastatic cancer[J]. Small, 2014, 10(3): 524-535.

[16] Houghton PJ, Kurmasheva RT, Kolb EA, et al. Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP)[J]. Pediatr Blood Cancer, 2015, 62(7): 1214-1221.

[17] Zhang M, Viennois E, Prasad M, et al. Edible ginger-derived nanoparticles: a novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer[J]. Biomaterials, 2016, 101: 321-340.

[18] Qin T, Ma TY, Huang K, et al. Lipoprotein (a)-related inflammatory imbalance: a novel horizon for the development of atherosclerosis[J]. Curr Atheroscler Rep, 2024, 26(8): 383-394.

[19] Shields CW, Evans MA, Wang LL, et al. Cellular backpacks for macrophage immunotherapy[J]. Sci Adv, 2020, 6(18): eaaz6579.

[20] Tang L, Zheng Y, Melo MB, et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery[J]. Nat Biotechnol, 2018, 36(8): 707-716.

[21] Chen X, Gao M, An S, et al. Enhancing adoptive T cell therapy for solid tumor with cell-surface anchored immune checkpoint inhibitor nanogels[J]. Nanomedicine, 2022, 45: 102591.

[22] Fan X, Wang K, Lu Q, et al. Surface-anchored tumor microenvironment-responsive protein nanogel-platelet system for cytosolic delivery of therapeutic protein in the post-surgical cancer treatment[J]. Acta Biomater, 2022, 154: 412-423.

[23] Shen N, Qi X, Bagrov DV, et al. Surface modification of fibroblasts with peroxiredoxin-1-loaded polymeric microparticles increases cell mobility, resistance to oxidative stress and collagen I production[J]. Colloids Surf B Biointerfaces, 2022, 219: 112834.

[24] Ci T, Li H, Chen G, et al. Cryo-shocked cancer cells for targeted drug delivery and vaccination[J]. Sci Adv, 2020, 6(50): eabc3013.

[25] Wang J, Pan H, Li J, et al. Cell membrane-coated mesoporous silica nanorods overcome sequential drug delivery barriers against colorectal cancer[J]. Chin Chem Lett, 2023, 34 (6): 107828.

[26] Wu C, Yan J, Ge C, et al. Macrophage membrane-reversibly camouflaged nanotherapeutics accelerate fracture healing by fostering MSCs recruitment and osteogenic differentiation[J]. J Nanobiotechnol, 2024, 22(1): 411.

[27] Cao Z, Liu X, Zhang W, et al. Biomimetic macrophage membrane-camouflaged nanoparticles induce ferroptosis by promoting mitochondrial damage in glioblastoma[J]. ACS Nano, 2023, 17(23): 23746-23760.

[28] Peng Y, Zhan M, Karpus A, et al. Brain delivery of biomimetic phosphorus dendrimer/antibody nanocomplexes for enhanced glioma immunotherapy via immune modulation of T cells and natural killer cells[J]. ACS Nano, 2024, 18(14): 10142-10155.

[29] Sun J, Ju F, Jin J, et al. M2 macrophage membrane-mediated biomimetic-nanoparticle carrying COX-siRNA targeted delivery for prevention of tendon adhesions by inhibiting inflammation[J]. Small, 2023, 19(33): e2300326.

[30] Liu Y, He M, Yuan Y, et al. Neutrophil-membrane-coated biomineralized metal-organic framework nanoparticles for atherosclerosis treatment by targeting gene silencing[J]. ACS Nano, 2023, 17(8): 7721-7732.

[31] Xu J, Chen T, Sun T, et al. Erythrocyte membrane camouflaged siRNA/chemodrug nanoassemblies for cancer combination therapy[J]. Biomater Sci, 2022, 10(22): 6601-6613.

[32] Fei S, Ma Y, Zhou B, et al. Platelet membrane biomimetic nanoparticle-targeted delivery of TGF-β1 siRNA attenuates renal inflammation and fibrosis[J]. Int J Pharm, 2024, 659: 124261.

[33] Qiu C, Han HH, Sun J, et al. Regulating intracellular fate of siRNA by endoplasmic reticulum membrane-decorated hybrid nanoplexes[J]. Nat Commun, 2019, 10: 2702.

[34] Zhuang J, Gong HH, Zhou J, et al. Targeted gene silencing in vivo by platelet membrane-coated metal-organic framework nanoparticles[J]. Sci Adv, 2020, 6(13): eaaz6108.

[35] Liu F, Meng F, Yang Z, et al. Exosome-biomimetic nanocarriers for oral drug delivery[J]. Chin Chem Lett, 2024, 35(9): 109335.

[36] Zheng L, Hu B, Zhao D, et al. Recent progresses of exosome-liposome fusions in drug delivery[J]. Chin Chem Lett, 2024, 35(2): 108647.

[37] Tikhonov A, Kachanov A, Yudaeva A, et al. Biomimetic nanoparticles for basic drug delivery[J]. Pharmaceutics, 2024, 16(10): 1306.

[38] Chen Y, Zhu Q, Cheng L, et al. Exosome detection via the ultrafast-isolation system: EXODUS[J]. Nat Methods, 2021, 18(2): 212-218.

[39] Haney MJ, Klyachko NL, Zhao Y, et al. Exosomes as drug delivery vehicles for Parkinson’s disease therapy[J]. J Control Release, 2015, 207: 18-30.

[40] Xiang X, Chen J, Jiang T, et al. Milk-derived exosomes carrying siRNA-KEAP1 promote diabetic wound healing by improving oxidative stress[J]. Drug Deliv Transl Res, 2023, 13(9): 2286-2296.

[41] Rodríguez-Morales B, Antunes-Ricardo M, González-Valdez J. Exosome-mediated insulin delivery for the potential treatment of diabetes mellitus[J]. Pharmaceutics, 2021, 13(11): 1870.

[42] Kim G, Kim M, Lee Y, et al. Systemic delivery of microRNA-21 antisense oligonucleotides to the brain using T7-peptide decorated exosomes[J]. J Control Release, 2020, 317: 273-281.

[43] Kojima R, Bojar D, Rizzi G, et al. Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson’s disease treatment[J]. Nat Commun, 2018, 9: 1305.

[44] Shrivastava S, Ray RM, Holguin L, et al. Exosome-mediated stable epigenetic repression of HIV-1[J]. Nat Commun, 2021, 12(1): 5541.

[45] Abouelnazar FA, Zhang X, Zhang J, et al. SALL4 promotes angiogenesis in gastric cancer by regulating VEGF expression and targeting SALL4/VEGF pathway inhibits cancer progression[J]. Cancer Cell Int, 2023, 23(1): 149.

[46] Dinh PC, Paudel D, Brochu H, et al. Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis[J]. Nat Commun, 2020, 11(1): 1064.

[47] Wang Z, Popowski KD, Zhu D, et al. Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine[J]. Nat Biomed Eng, 2022, 6(7): 791-805.

[48] Wang F, Qian J, Yang MY, et al. MiR-6924-5p-rich exosomes derived from genetically modified Scleraxis-overexpressing PDGFRα( + ) BMMSCs as novel nanotherapeutics for treating osteolysis during tendon-bone healing and improving healing strength[J]. Biomaterials, 2021, 279: 121242.

[49] Wu L, Wang L, Liu X, et al. Milk-derived exosomes exhibit versatile effects for improved oral drug delivery[J]. Acta Pharm Sin B, 2022, 12(4): 2029-2042.

[50] Xiao P, Wang H, Liu H, et al. Milk exosome-liposome hybrid vesicles with self-adapting surface properties overcome the sequential absorption barriers for oral delivery of peptides[J]. ACS Nano, 2024, 18(32): 21091-21111.

[51] Yin L, Yan L, Yu Q, et al. Characterization of the microRNA profile of ginger exosome-like nanoparticles and their anti-inflammatory effects in intestinal Caco-2 cells[J]. J Agric Food Chem, 2022, 70(15): 4725-4734.

[52] Teng Y, Ren Y, Sayed M, et al. Plant-derived exosomal microRNAs shape the gut microbiota[J]. Cell Host Microbe, 2018, 24(5): 637-652.

[53] Zhuang X, Deng ZB, Mu J, et al. Ginger-derived nanoparticles protect against alcohol-induced liver damage[J]. J Extracell Vesicles, 2015, 4(1): 28713.

[54] Man F, Meng C, Liu Y, et al. The study of ginger-derived extracellular vesicles as a natural nanoscale drug carrier and their intestinal absorption in rats[J]. AAPS PharmSciTech, 2021, 22(6): 206.

[55] Wang X, Zhang M, Woloshun RR, et al. Oral administration of ginger-derived lipid nanoparticles and dmt1 siRNA potentiates the effect of dietary iron restriction and mitigates pre-existing iron overload in KO mice[J]. Nutrients, 2021, 13(5): 1686.

[56] Li Z, Wang H, Yin H, et al. Arrowtail RNA for ligand display on ginger exosome-like nanovesicles to systemic deliver siRNA for cancer suppression[J]. Sci Rep, 2018, 8: 14644.

[57] Huang W, Zhang Q, Li W, et al. Development of novel nanoantibiotics using an outer membrane vesicle-based drug efflux mechanism[J]. J Control Release, 2020, 317: 1-22.

[58] Liu G, Ma N, Cheng K, et al. Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity[J]. Nat Nanotechnol, 2024, 19(3): 387-398.

[59] Gujrati V, Kim S, Kim SH, et al. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy[J]. ACS Nano, 2014, 8(2): 1525-1537.

[60] Tashiro Y, Hasegawa Y, Shintani M, et al. Interaction of bacterial membrane vesicles with specific species and their potential for delivery to target cells[J]. Front Microbiol, 2017, 8: 571.

[61] Chen Q, Bai H, Wu W, et al. Bioengineering bacterial vesicle-coated polymeric nanomedicine for enhanced cancer immunotherapy and metastasis prevention[J]. Nano Lett, 2020, 20(1): 11-21.

[62] Lin H, Han R, Wu W. Glucans and applications in drug delivery[J]. Carbohydr Polym, 2024, 332: 121904.

[63] Yan Y, Lu A, Dou Y, et al. Nanomedicines reprogram synovial macrophages by scavenging nitric oxide and silencing CA9 in progressive osteoarthritis[J]. Adv Sci (Weinh), 2023, 10(11): e2207490.

[64] Cui SH, Yan Y, Lu A, et al. Nanomedicines promote cartilage regeneration in osteoarthritis by synergistically enhancing chondrogenesis of mesenchymal stem cells and regulating inflammatory environment[J]. ACS Nano, 2024, 18(11): 8125-8142.

[65] Gharehdaghi EE, Amani A, Khoshayand MR, et al. Chitosan nanoparticles for siRNA delivery: optimization of processing/formulation parameters[J]. Nucleic Acid Ther, 2014, 24(6): 420-427.

[66] Sudhakar S, Chandran SV, Selvamurugan N, et al. Biodistribution and pharmacokinetics of thiolated chitosan nanoparticles for oral delivery of insulin[J]. Int J Biol Macromol, 2020, 150: 281-288.

[67] Liu C, Tang C, Yin C. Co-delivery of doxorubicin and siRNA by all-trans retinoic acid conjugated chitosan-based nanocarriers for multiple synergistic antitumor efficacy[J]. Carbohydr Polym, 2022, 283: 119097.

[68] Jiang Y, Stenzel M. Drug Delivery Vehicles Based on Albumin-Polymer Conjugates[J]. Macromol Biosci, 2016, 16(6): 791-802.

[69] Azevedo C, Nilsen J, Grevys A, et al. Engineered albumin-functionalized nanoparticles for improved FcRn binding enhance oral delivery of insulin[J]. J Control Release, 2020, 327: 161-173.

[70] Wasko J, Wolszczak M, Zajaczkowska Z, et al. Human serum albumin as a potential drug delivery system for N-methylated hot spot insulin analogs inhibiting hormone aggregation[J]. Bioorg Chem, 2024, 143: 107104.

[71] Li L, Muñoz-Culla M, Carmona U, et al. Ferritin-mediated siRNA delivery and gene silencing in human tumor and primary cells[J]. Biomaterials, 2016, 98: 143-151.

[72] Pediconi N, Ghirga F, Del Plato C, et al. Design and synthesis of piperazine-based compounds conjugated to humanized ferritin as delivery system of siRNA in cancer cells[J]. Bioconjug Chem, 2021, 32(6): 1105-1116.

[73] Choi KM, Choi SH, Jeon H, et al. Chimeric capsid protein as a nanocarrier for siRNA delivery: stability and cellular uptake of encapsulated siRNA[J]. ACS Nano, 2011, 5(11): 8690-8699.

[74] Choi KM, Kim K, Kwon IC, et al. Systemic delivery of siRNA by chimeric capsid protein: tumor targeting and RNAi activity[J]. Mol Pharm, 2013, 10(1): 18-25.

[75] Cano-Garrido O, Rodríguez-Carmona E, Díez-Gil C, et al. Supramolecular organization of protein-releasing functional amyloids solved in bacterial inclusion bodies[J]. Acta Biomater, 2013, 9(4): 6134-6142.

[76] Lin W, Zheng X, Wang H, et al. Purification and characterization of a novel cell-penetrating carrier similar to cholera toxin chimeric protein[J]. Protein Expr Purif, 2017, 129: 128-134.

[77] Voráčková I, Ulbrich P, Diehl WE, et al. Engineered retroviral virus-like particles for receptor targeting[J]. Arch Virol, 2014, 159(4): 677-688.

[78] Sun W, Taylor CS, Gao Z, et al. Co-assembling bioactive short peptide nanofibers coated silk scaffolds induce neurite outgrowth of PC12 cells[J]. Int J Biol Macromol, 2024, 278: 134774.

[79] Mazza M, Hadjidemetriou M, de Lázaro I, et al. Peptide nanofiber complexes with siRNA for deep brain gene silencing by stereotactic neurosurgery[J]. ACS Nano, 2015, 9(2): 1137-1149.

[80] Yamada Y, Perez SM, Tabata M, et al. Efficient and high-speed transduction of an antibody into living cells using a multifunctional nanocarrier system to control intracellular trafficking[J]. J Pharm Sci, 2015, 104(9): 2845-2854.

[81] Seeman NC. DNA in a material world[J]. Nature, 2003, 421(6921): 427-431.

[82] Li G, Chen C, Li Y, et al. DNA-origami-based precise molecule assembly and their biological applications[J]. Nano Lett, 2024, 24(37): 11335-11348.

[83] Knappe GA, Wamhoff EC, Bathe M. Functionalizing DNA origami to investigate and interact with biological systems[J]. Nat Rev Mater, 2023, 8(2): 123-138.

[84] Li S, Jiang Q, Liu S, et al. A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger[J]. Nat Biotechnol, 2018, 36(3): 258-264.

[85] Lee H, Lytton-Jean AK, Chen Y, et al. Molecularly self-assembled nucleic acid nanoparticles for targeted siRNA delivery[J]. Nat Nanotechnol, 2012, 7(6): 389-393.

[86] Guo W, Gao H, Li H, et al. Self-assembly of a multifunction DNA tetrahedron for effective delivery of aptamer PL1 and siRNA potentiate immune checkpoint therapy for colorectal cancer[J]. ACS Appl Mater Interfaces, 2022, 14(28): 31634-31644.

[87] Rahman MA, Wang P, Zhao Z, et al. Systemic delivery of Bc12-targeting siRNA by DNA nanoparticles suppresses cancer cell growth[J]. Angew Chem Int Ed Engl, 2017, 56(50): 16023-16027.

[88] Shi R, Zhu Y, Chen Y, et al. Advances in DNA nanotechnology for chronic wound management: Innovative functional nucleic acid nanostructures for overcoming key challenges[J]. J Control Release, 2024, 375: 155-177.

Funding

National Natural Science Foundation of China(82273884)